https://www.selleckchem.com/pr....oducts/iwr-1-endo.ht
The aim of the present study based on the PriCoTTF-phase I/II trial is the quantification of skin-normal tissue complication probabilities of patients with newly diagnosed glioblastoma multiforme treated with Tumor Treating Field (TTField) electrodes, concurrent radiotherapy, and temozolomide. Furthermore, the skin-sparing effect by the clinically applied strategy of repetitive transducer array fixation around their center position shall be examined. Low-dose cone-beam computed tomography (CBCT) scans of all fractions of the first se
Like
Comment
Share
